Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease. your-feed-science, Falsification of Data, Clinical Trials, Regulation and Deregulation of Industry, Alzheimer’s Disease, Decisions and Verdicts, Research, Securities and Commodities Violations, Cassava Sciences Inc, simufilam Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease. NYT > Business
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
